Project Grant HT94252411016
Award Date
9/15/24
Completion Date
9/14/26
Dollars Obligated
$709K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
The University of California, Los Angeles (UCLA) has been awarded a $472,500 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund the development of a next-generation, off-the-shelf CAR-NKT cell therapy for the treatment of metastatic clear cell renal cell carcinoma. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $630,000.00 to the University of California, Los Angeles (UCLA) for intravesical nectin4 chimeric antigen receptor T cell therapy research for non-muscle invasive bladder cancer. The award period runs from September 1, 2024 to August 31, 2026. As the prime awardee, UCLA will leverage its facilities, faculty expertise, and administrative capabilities...
The U.S. Department of Defense's Defense Health Agency awarded a $1,037,990 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420) to develop a safe small molecule approach to prevent kidney cancer metastasis. The three-year grant, which began on September 1, 2023, will support UCLA's research efforts to investigate new treatments for kidney cancer that could benefit military service members and the general...
This Project Grant award from the Defense Health Agency provides $979,875 to Dana-Farber Cancer Institute, Inc. for research under the Military Medical Research and Development program. The award aims to further optimize dual-targeted CAR T cells to achieve cures for advanced clear cell renal cell carcinoma (CCRCC) by fine-tuning CAR constructs against carbonic anhydrase IX and CD70 antigens based on tumor expression levels. Brigham and Women's Hospital, Inc. will receive a sub-award to...
The University of California, Los Angeles (UCLA) was awarded a $961,089 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research targeting mitochondrial defects in kidney cancer from September 1, 2022 to August 31, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military...
This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
This federal Project Grant award, totaling $1,163,420.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to the University of California, Davis. The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The research aims to investigate functional and phenotypic metabolic transitions governing disease state in clear cell renal cell...
This federal Project Grant award of $188,403 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research at the University of California, Los Angeles (UCLA) to develop new cell-mediated immunotherapeutic strategies for small-cell lung cancer. The award, effective from January 1, 2025 to December 31, 2025, will fund advanced biomedical research initiatives at UCLA targeting innovative treatments for this form of lung cancer. The Military...
This Project Grant award, valued at $543,285.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the University of Washington will conduct research to develop new FDA-approved combination therapies for transforming the treatment of rhabdomyosarcoma, a rare...